Cargando…

Pemetrexed in Previously Treated Non-small Cell Lung Cancer Patients with Poor Performance Status

BACKGROUND AND OBJECTIVE: Pemetrexed have been approved for the treatment of patients affected by advanced non-small cell lung cancner (NSCLC) in progression after first-line chemotherapy. We evaluated the activity and feasibility of pemetrexed in previously treated NSCLC. METHODS: Patients with his...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Young JUNG, Su, Jin YOO, Ji, Young SHIN, Ji, Won PARK, Jeong, Eun LEE, Hee, Sun PARK, Ju, Ock KIM, Sun, Young KIM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999695/
https://www.ncbi.nlm.nih.gov/pubmed/21219829
http://dx.doi.org/10.3779/j.issn.1009-3419.2011.01.07
_version_ 1783331481374949376
author Sun, Young JUNG
Su, Jin YOO
Ji, Young SHIN
Ji, Won PARK
Jeong, Eun LEE
Hee, Sun PARK
Ju, Ock KIM
Sun, Young KIM
author_facet Sun, Young JUNG
Su, Jin YOO
Ji, Young SHIN
Ji, Won PARK
Jeong, Eun LEE
Hee, Sun PARK
Ju, Ock KIM
Sun, Young KIM
author_sort Sun, Young JUNG
collection PubMed
description BACKGROUND AND OBJECTIVE: Pemetrexed have been approved for the treatment of patients affected by advanced non-small cell lung cancner (NSCLC) in progression after first-line chemotherapy. We evaluated the activity and feasibility of pemetrexed in previously treated NSCLC. METHODS: Patients with histologically or cytologically confirmed NSCLC were evaluated from April 2007 to March 2009. The patients had relapsed or progressed after prior chemotherapy treatment. Pemetrexed (500 mg/m(2)) was administered intravenously once every 3 weeks after progression to prior chemotherapy. The tumor response was evaluated according to RECIST criteria by chest CT at every 2 cycles of chemotherapy. RESULTS: A total 61 patients were eligible for analysis. Performance status of them (100%) was over 2. The response rate and disease control rate were 14.7% and 37.7% respectively. Non-squamous cell carcinoma histology was significantly associated with a superior response rate (P=0.045) and disease control rate (P=0.008). The median survival time and the median progression free survival (PFS) time were 6.11 months and 2.17 months, respectively. Comparing the efficacy of pemetrexed in these two settings [second-line versus (12/61) more than third (49/61)], there was no significant difference in regard to median survival (11.18 months vs 11.46 months, P=0.922, 5), but PFS was more longer in third- or further-line groups than second-line group (1.39 months vs 2.25 months, P=0.015, 3). CONCLUSION: Pemetrexed is a feasible regimen in previously treated NSCLC with poor performance status.
format Online
Article
Text
id pubmed-5999695
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-59996952018-07-06 Pemetrexed in Previously Treated Non-small Cell Lung Cancer Patients with Poor Performance Status Sun, Young JUNG Su, Jin YOO Ji, Young SHIN Ji, Won PARK Jeong, Eun LEE Hee, Sun PARK Ju, Ock KIM Sun, Young KIM Zhongguo Fei Ai Za Zhi Clinical Research BACKGROUND AND OBJECTIVE: Pemetrexed have been approved for the treatment of patients affected by advanced non-small cell lung cancner (NSCLC) in progression after first-line chemotherapy. We evaluated the activity and feasibility of pemetrexed in previously treated NSCLC. METHODS: Patients with histologically or cytologically confirmed NSCLC were evaluated from April 2007 to March 2009. The patients had relapsed or progressed after prior chemotherapy treatment. Pemetrexed (500 mg/m(2)) was administered intravenously once every 3 weeks after progression to prior chemotherapy. The tumor response was evaluated according to RECIST criteria by chest CT at every 2 cycles of chemotherapy. RESULTS: A total 61 patients were eligible for analysis. Performance status of them (100%) was over 2. The response rate and disease control rate were 14.7% and 37.7% respectively. Non-squamous cell carcinoma histology was significantly associated with a superior response rate (P=0.045) and disease control rate (P=0.008). The median survival time and the median progression free survival (PFS) time were 6.11 months and 2.17 months, respectively. Comparing the efficacy of pemetrexed in these two settings [second-line versus (12/61) more than third (49/61)], there was no significant difference in regard to median survival (11.18 months vs 11.46 months, P=0.922, 5), but PFS was more longer in third- or further-line groups than second-line group (1.39 months vs 2.25 months, P=0.015, 3). CONCLUSION: Pemetrexed is a feasible regimen in previously treated NSCLC with poor performance status. 中国肺癌杂志编辑部 2011-01-20 /pmc/articles/PMC5999695/ /pubmed/21219829 http://dx.doi.org/10.3779/j.issn.1009-3419.2011.01.07 Text en 版权所有©《中国肺癌杂志》编辑部2011 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle Clinical Research
Sun, Young JUNG
Su, Jin YOO
Ji, Young SHIN
Ji, Won PARK
Jeong, Eun LEE
Hee, Sun PARK
Ju, Ock KIM
Sun, Young KIM
Pemetrexed in Previously Treated Non-small Cell Lung Cancer Patients with Poor Performance Status
title Pemetrexed in Previously Treated Non-small Cell Lung Cancer Patients with Poor Performance Status
title_full Pemetrexed in Previously Treated Non-small Cell Lung Cancer Patients with Poor Performance Status
title_fullStr Pemetrexed in Previously Treated Non-small Cell Lung Cancer Patients with Poor Performance Status
title_full_unstemmed Pemetrexed in Previously Treated Non-small Cell Lung Cancer Patients with Poor Performance Status
title_short Pemetrexed in Previously Treated Non-small Cell Lung Cancer Patients with Poor Performance Status
title_sort pemetrexed in previously treated non-small cell lung cancer patients with poor performance status
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999695/
https://www.ncbi.nlm.nih.gov/pubmed/21219829
http://dx.doi.org/10.3779/j.issn.1009-3419.2011.01.07
work_keys_str_mv AT sunyoungjung pemetrexedinpreviouslytreatednonsmallcelllungcancerpatientswithpoorperformancestatus
AT sujinyoo pemetrexedinpreviouslytreatednonsmallcelllungcancerpatientswithpoorperformancestatus
AT jiyoungshin pemetrexedinpreviouslytreatednonsmallcelllungcancerpatientswithpoorperformancestatus
AT jiwonpark pemetrexedinpreviouslytreatednonsmallcelllungcancerpatientswithpoorperformancestatus
AT jeongeunlee pemetrexedinpreviouslytreatednonsmallcelllungcancerpatientswithpoorperformancestatus
AT heesunpark pemetrexedinpreviouslytreatednonsmallcelllungcancerpatientswithpoorperformancestatus
AT juockkim pemetrexedinpreviouslytreatednonsmallcelllungcancerpatientswithpoorperformancestatus
AT sunyoungkim pemetrexedinpreviouslytreatednonsmallcelllungcancerpatientswithpoorperformancestatus